House lawmakers' latest target in addressing high drug prices: Generic competition
March 14, 2019 / Tina Reed
Tactics used by drug companies to delay generic competition are the target of a collection of bills being considered by lawmakers in the latest efforts to address the high price of precision drugs. “For too long, people have been subjected to the abuse of the patent system by pharmaceutical companies and generic companies entering into agreements and employing tactics that block the competition and keep prices high,” Rep. Anna Eshoo, D-Calif., during a hearing by the House Committee on Energy & Commerce Health subcommittee on Wednesday. The subcommittee had seven potential measures to consider, including bills aimed at addressing drug company tactics used to restrict access by generic drug makers to their samples or to pay generic competitors with exclusivity to delay the release of a generic competitor.